| Patient | Martha Canary |
|---|---|
| Date of birth | 1981-05-01 |
| Identifiers | MRN HR-NI008-SYN; SSN (made up) 000-08-9532 |
| Document date | 2026-06-22 |
| Author | Ruth Ann Kessler, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Sixteen-week review after a two-day return to drinking. [S]
Ms. Canary returns six weeks after her ten-week review. Her third injection was due four weeks after the second, but she was away for ranch work and it was given four days late. On the two days before it, after a hard week, she drank about half a pint of whiskey each day. On the second day she called the peer recovery specialist, who met her the next morning and brought her to the nurse for the injection. She has had no alcohol in the three weeks since and had no shakes or sweats. She told us about it herself and was afraid we would be angry. Her mammogram at the mobile unit last week was normal. She is eating two or three meals a day. [S]
| Element | Detail |
|---|---|
| Alcohol | Two days of drinking about four weeks ago, about half a pint a day; none in the three weeks since |
| Naltrexone | Third injection four days late; next due in four days |
| Withdrawal | None |
| Mood | PHQ-9 5; GAD-7 5 |
| Mammogram | Normal |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight rising |
| Gastrointestinal | Negative | No abdominal pain, vomiting or yellowing |
| Neurological | Negative | No tremor or confusion |
| Psychiatric | Positive | Ashamed of the lapse at first, now determined; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Gabapentin 300 mg oral capsule on a written five-day schedule for alcohol withdrawal: 300 mg in the morning, 300 mg in the afternoon and 600 mg at bedtime for three days, then 300 mg twice daily on day four, 300 mg at bedtime on day five, then stop; dispensed for the five days only | Per the written five-day schedule | Oral route | 2026-03-02 to 2026-03-06 | completed | S |
| Thiamine 100 mg by intramuscular injection once daily for three days, given in the clinic | 100 mg intramuscularly once daily for three days | Intramuscular route | 2026-03-02 to 2026-03-04 | completed | S |
| Thiamine 100 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-05 | active | S |
| Folic acid 1 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 | active | S |
| Potassium chloride extended-release 20 mEq oral tablet, one tablet daily with food for five days | One tablet daily with food for five days | Oral route | 2026-03-02 to 2026-03-06 | completed | S |
| Magnesium oxide 400 mg oral tablet, one tablet twice daily for two weeks | One tablet twice daily for two weeks | Oral route | 2026-03-02 to 2026-03-16 | completed | S |
| Naltrexone 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 to 2026-03-30 | completed | S |
| Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse | 380 mg intramuscularly every four weeks | Intramuscular route | 2026-03-30 | active | S |
| Amoxicillin 500 mg oral capsule, one capsule three times daily for five days | One capsule three times daily for five days | Oral route | 2026-03-23 to 2026-03-28 | completed | S |
| Ibuprofen 400 mg oral tablet, one tablet with food every 8 hours as needed for tooth pain, for up to five days | One tablet with food every 8 hours as needed, up to five days | Oral route | 2026-03-23 to 2026-03-28 | completed | S |
| Acetaminophen 500 mg oral tablet, one tablet every 6 hours as needed with the ibuprofen, no more than 2,000 mg a day, for up to five days | One tablet every 6 hours as needed, no more than 2,000 mg a day | Oral route | 2026-03-23 to 2026-03-28 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-22 | Body height | 165 | cm | S |
| 2026-06-22 | Body weight | 52.6 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 72 | /min | S |
| 2026-06-22 | Respiratory rate | 16 | /min | S |
| 2026-06-22 | Body temperature | 36.6 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-22 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-22 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 95 | fL | 80-100 fL | Normal | S |
| 2026-06-22 | Platelets [#/volume] in Blood by Automated count | 214 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-22 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-22 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 111 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-22 | Glucose [Mass/volume] in Serum or Plasma | 84 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-35 U/L | Normal | S |
| 2026-06-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-06-22 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 58 | U/L | 5-40 U/L | High | S |
| 2026-06-22 | Albumin [Mass/volume] in Serum or Plasma | 3.9 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-06-22 | Phosphatidylethanol [Mass/volume] in Blood | 64 | ng/mL | <=20 ng/mL | High | S |
| 2026-06-22 | Liver stiffness by US.transient elastography | 6.8 | kPa | <=8 kPa | Normal | S |
| 2026-06-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-06-22 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
Vital signs recorded on 2026-06-22; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 72; weight 52.6 kg, BMI 19.3 |
| Eyes | No scleral icterus |
| Abdomen | Soft and non-tender; no ascites |
| Neurological | No tremor |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Alcohol use disorder, severe (nine of eleven DSM-5-TR criteria), daily drinking of about a pint of whiskey with heavier binges for many years; synthetic modern episode linked to her documented lifelong heavy drinking | active | confirmed | F10.20 | S — Synthetic modern coding; DSM-5-TR severe alcohol use disorder maps to F10.20 when withdrawal is coded separately. Person-first language; not a claim about her real diagnosis. |
| Alcohol withdrawal, mild, at low risk of complications (PAWSS 3, CIWA-Ar 9 at intake; no past seizures or delirium tremens), managed as an outpatient with daily nurse checks | resolved | confirmed | F10.230 | S — Synthetic withdrawal episode; resolved by the one-week visit. |
| Raised liver enzymes (AST 96, ALT 44, GGT 240 U/L) with a FIB-4 index of 3.93, above the cut point for possible advanced fibrosis; liver stiffness measurement planned | resolved | confirmed | R74.01 | S — Synthetic presenting finding; superseded when elastography and the clinical picture supported alcohol-associated steatotic liver disease. |
| Alcohol-associated steatotic liver disease, without cirrhosis: liver stiffness 9.6 kPa after four weeks without alcohol, falling enzymes, normal bilirubin, albumin, INR and platelets | active | confirmed | K70.0 | S — Synthetic modern diagnosis made at the four-week visit. |
| Depressive symptoms during heavy drinking (PHQ-9 14, item 9 scored 0); whether they are alcohol-induced or an independent depression to be judged after two to four weeks without alcohol | resolved | provisional | F32.A | S — Synthetic provisional finding; resolved as the PHQ-9 fell to 5 after ten weeks without alcohol, consistent with alcohol-induced depressive symptoms. Not a claim about her real mood. |
| Daily chewing tobacco for many years; not ready to stop at intake | active | confirmed | F17.220 | S — Synthetic modern coding anchored to the documented chewing tobacco. |
| Underweight (BMI 18.4) with poor food intake, low folate, magnesium and phosphate, and slightly low albumin | active | confirmed | R63.6 | S — Synthetic finding anchored to a contemporary impression of poor nutrition (R). |
| Housing instability: staying in a spare room at a friend's house, with nowhere to go if that ends; has stayed in shelters in past winters | active | confirmed | Z59.811 | S — Synthetic social need anchored to her documented poverty and moves from town to town. |
| Food insecurity: often goes without meals at the end of the month | active | confirmed | Z59.41 | S — Synthetic social need anchored to her documented poverty. |
| Periapical abscess of a lower left molar with facial swelling and low-grade fever, on naltrexone; treated without opioids, tooth removed at the dental clinic the next day; resolved | resolved | confirmed | K04.7 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | Two days of drinking about four weeks ago; none since |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Completed today | 64 ng/mL, consistent with her account of two days of drinking |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Thiamine and folic acid continued; hemoglobin 13.1 g/dL, MCV 95 fL; sodium 139, potassium 4.2 mmol/L, creatinine 0.66 mg/dL, eGFR 111, glucose 84 mg/dL |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every four weeks, on time | Deferred | The third injection was given four days late because she was away for work, and the two days of drinking came just before it. No lasting harm: she stopped within two days, had no withdrawal, and her liver tests and elastography improved. Corrective action: injections are booked on days she chooses, with a reminder call and a ride from the peer specialist |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Completed today | AST 31, ALT 24 U/L, normal; GGT 58 U/L |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Completed today | Liver stiffness 6.8 kPa; albumin 3.9 g/dL; platelets 214; FIB-4 1.30 |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 52.6 kg, BMI 19.3; two or three meals a day |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Completed today | PHQ-9 5, item 9 scored 0; GAD-7 5; no low mood after the lapse |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm after the lapse; rifle stored; 988 in her phone |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Weekly calls; the peer specialist met her the morning after the lapse; a second weekly contact added |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Still in her room; rent assistance renewed |
| Self-management | Chewing tobacco | Every visit | Completed today | Cutting down; would like to try nicotine lozenges next month |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), second of two doses [S]
Guideline basis: The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The Healthcare Professional's Core Resource on Alcohol (2026); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Second hepatitis B dose given today. Naltrexone injection in four days at a nurse visit. Review in two months. Second hepatitis A dose in four months. Call the peer specialist, the clinic or 988 at any time. [S]